Biotech awaits results

Drug maker Pharmaxis is sweating on the results of a clinical trial of cystic fibrosis drug Bronchitol.

By InvestSMART · 23 Apr 2013

By InvestSMART ·
23 Apr 2013

Comments

Drug maker Pharmaxis is sweating on the results of a clinical trial of cystic fibrosis drug Bronchitol. The biotech placed its shares in a trading halt on Monday before the results of the phase III trial, expected this week. The move was just two months after the drug was rejected by the main US regulatory body, which sent Pharmaxis shares into a tailspin.

Go to Google News, then click "Follow" button to add us.

Share this article and show your support

Frequently Asked Questions about this Article…

What is Pharmaxis waiting for right now?

Pharmaxis is awaiting the results of a phase III clinical trial for its cystic fibrosis drug Bronchitol, with the trial results expected this week.

Why did Pharmaxis place its shares in a trading halt?

The company placed its shares in a trading halt on Monday ahead of the phase III trial results for Bronchitol, pausing trading while investors await the outcome.

What is Bronchitol and what condition is it intended to treat?

Bronchitol is a drug developed by Pharmaxis intended to treat cystic fibrosis, and the company is awaiting results from a phase III clinical trial.

Which phase of clinical testing is Bronchitol currently in?

Bronchitol is in a phase III clinical trial, and results from that trial are expected this week according to the article.

Has Bronchitol faced regulatory challenges recently?

Yes — the drug was rejected by the main US regulatory body about two months before the company announced the trading halt, a development that affected investor sentiment.

How did the US regulator's decision affect Pharmaxis shares?

The US regulatory rejection sent Pharmaxis shares into a tailspin, according to the article.

When will investors likely know the phase III trial outcome for Bronchitol?

The phase III trial results are expected this week, and Pharmaxis placed a trading halt on its shares immediately before those results were due.

What should investors watch for in the coming days regarding Pharmaxis?

Investors should watch for the upcoming phase III trial results for Bronchitol and any company announcements following the trading halt, as reported in the article.